The presence of autoantibodies to cytoplasmic rod and ring particles in the serum of patients with chronic hepatitis C virus infection by Afsharzadeh, F. et al.
Hepat Mon. 2016 December; 16(12):e42388.
Published online 2016 December 11.
doi: 10.5812/hepatmon.42388.
Research Article
The Presence of Autoantibodies to Cytoplasmic Rod and Ring Particles
in the Serum of Patients with Chronic Hepatitis C Virus Infection
Fatemeh Afsharzadeh,1 Farah Bokharaei-Salim,1,2,* Maryam Esghaei,1 Seyed Hamidreza Monavari,1
Shahin Merat,3 Hossein Poustchi,3 Arghavan Haj-Sheykholeslami,3,4 and Hossein Keyvani1,*
1Department of Virology, Iran University of Medical Sciences, Tehran, IR Iran
2HIV Laboratory of National Center, Deputy of Health, Iran University of Medical Sciences, Tehran, IR Iran
3Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran
4Department of Community Medicine, Iran University of Medical Sciences, Tehran, IR Iran
*Corresponding authors: Farah Bokharaei-Salim, Department of Virology, Iran University of Medical Sciences, Tehran, IR Iran. Tel/Fax: +98-2166047831, E-mail:
bokharaei.f@iums.ac.ir; Hossein Keyvani, Department of Virology, Iran University of Medical Sciences, Tehran, IR Iran. Tel/Fax: +98-2188706555, E-mail: Keyvanlab@yahoo.com
Received 2016 September 19; Revised 2016 October 20; Accepted 2016 November 29.
Abstract
Background: Chronic hepatitis C virus (HCV) is associated with extra hepatic autoimmune disorders, while peg-IFNa-2a/RBV combi-
nation therapy may exacerbate these conditions. Autoantibodies to cytoplasmic structures, called rod and ring particles (RR), have
strong associations with these patients and are identified by HEp-2 cells.
Objectives: Our purpose was to study the correlation of autoantibodies to cytoplasmic rod and ring particles in the serum of pa-
tients with chronic HCV infection with their response to standard therapy.
Methods: Serum samples were gathered from 120 patients with HCV infection (40 naive treatments, 40 with sustained virological
response (SVR), and 40 with relapse response) during peg-IFNa-2a/RBV combination therapy and analyzed for the presence of RR
antibodies by IIF on commercially available HEp-2 cell substrate slides from Euroimmun (Lu beck, Germany).
Results: Anti-rod and ring (anti-RR) autoantibodies were detected in only the serum of 1 out of 120 patients (0.8%), which belonged
to a patient (out of 40) with relapse response (2.5%). No correlation was found between the types of response to peg-IFNa-2a/RBV
combination therapy and the presence of anti-RR autoantibodies.
Conclusions: The only HCV patient with RR autoantibodies previously had received IFN/ribavirin antiviral therapy. The presence
of these autoantibodies is extremely rare in Iranian HCV patients. Further studies are warranted to determine the role of genetic
background and geographical pattern in the prevalence of these novel autoantibodies worldwide.
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1. Introduction
Hepatitis C virus (HCV) is an enveloped single stranded
RNA positive sense virus which is classified in the genus
Hepacivirus of the Flaviviridae family. It is a major cause of
chronic liver disease, possibly leading to liver cirrhosis and
hepatocellular carcinoma (1, 2). In the majority of the HCV
infected patients, the infection becomes chronic, but in 14%
- 45% of the cases, the virus is spontaneously cleared (3).
The last estimates of the disease burden show an increase
in seroprevalence over the last 15 years to 2.8%, equating to
more than 185 million infections worldwide (4). However,
the prevalence rate of HCV in Iran is low, where the rate in
the general population is < 0.5% (5, 6).
The virus genome encodes a polyprotein of approxi-
mately 3000 amino acids that is flanked by 5′ and 3′ non-
coding regions (5′-NCR and 3’-NCR) (7). Translation of the
polyprotein is mediated by an internal ribosome entry site
(IRES) embedded within the 5′-NCRs, and the individual vi-
ral proteins are produced upon cleavage of the polypro-
tein by host and viral proteases. These include three struc-
tural proteins (core, E1, and E2), the p7 protein, and six non-
structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B),
which are involved in virion assembly and viral RNA repli-
cation (8). The virus is classified into seven different geno-
types and more than a hundred subtypes (termed a, b, c,
etc.), and it also manifests itself in the sera or tissues of
patients with the appearance of quasispecies. The com-
mon treatment method for HCV infection is pegylated in-
terferon a-2a and ribavirin (peg-IFNa-2a/RBV) combination
therapy in developing countries (1).
This treatment is used to eradicate the infection and
reduce the risk of cirrhosis and hepatocellular carcinoma
(9). Treatment results have been shown to be affected by
various viral factors such as the HCV genotype or pretreat-
ment viral load and host factors such as fibrosis, cirrho-
sis, liver steatosis, and insulin resistance (10, 11). Recently,
there has been evidence showing that a genetic polymor-
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phism near the interleukin-28B gene encoding IFN-λ3 is
correlated with the treatment response (12, 13).
HCV infection is related to various immunological ab-
normalities, including the production of organ specific
and non-organ specific autoantibodies (autoAbs) (14). Or-
gan specific autoAbs consist of those produced against
their targets in pancreatic islet cells (15), thyroid (16), the
adrenal cortex (15), and gastric parietal cells (17). Non-
organ specific autoAbs cover anti-smooth muscle Abs, anti-
nuclear Abs (ANA), anti-neutrophil cytoplasmic Abs, anti-
mitochondrial Abs, and anti-liver-kidney microsomal Abs
(18).
These autoAbs are mainly divided into five groups: i)
autoAbs as serological markers for autoimmune liver dis-
ease; ii) autoAbs as serological markers for extra-hepatic
autoimmune diseases; iii) autoAbs to endocrine organs;
iv) autoAbs to tumor-associated antigens, and v) other au-
toAbs (19).
Since HCV penetrates into the hepatocytes through the
binding of its envelope protein (E2) to CD81, which is also
expressed in B-lymphocytes, Pileri et al. proposed that HCV
binding to B-cells lowers their activation threshold and be-
cause of that, the production of autoAbs is facilitated (20).
On the other hand, regarding peg-IFNa-2a/RBV combina-
tion therapy, the cornerstones of the control of HCV in-
fection have immunomodulatory effects (21), such as the
production of autoantibodies (22). A novel autoAb that
recognizes special cytoplasmic rod and ring (RR) struc-
tures was first identified in the sera of HCV patients that
were studied using commercial ANA slides (23). Inosine
monophosphate dehydrogenase 2 (IMPDH2) and cytidine
triphosphate synthase 1 (CTPS1) were identified as poten-
tial autoAbs targets, which are localized to the RR struc-
tures (23). Anti-rod and ring (anti-RR) autoAbs were specific
to HCV patients who were under peg-IFNa-2a/RBV combina-
tion therapy (24).
2. Objectives
The aim of the present study was to determine the re-
lationship between the presence of autoantibodies to the
cytoplasmic rod and ring particles in the serum of pa-
tients with chronic hepatitis C and the response to peg-
IFNa-2a/RBV combination therapy.
3. Methods
3.1. Study Population
The study was conducted on samples gathered from
120 chronic hepatitis C patients who referred to the diges-
tive disease research institute (DDRI) of Shariati hospital
affiliated to Tehran University of Medical Sciences (TUMS)
from 2010 to 2012. The samples were stored at -80°C. The ex-
clusion criteria included coinfection with human immun-
odeficiency virus (HIV) and hepatitis B virus (HBV) (25). The
current study was approved by the Ethics Committee of
Iran University of Medical Sciences (IUMS), Tehran, Iran.
3.2. Treatment Method
The patients were treated with standard combina-
tion therapy using pegylated IFNa-2a (Peg-IFNa-2a; Pegasys,
Roche, Basel, Switzerland), 180 µg per week, in combina-
tion with ribavirin (RBV) (Copegus, Roche), 1,000 - 1,200
mg per day. HCV infected patients with genotypes 1 and 4
were treated for 48 weeks, whereas genotype 3-HCV posi-
tive patients were treated for 24 weeks according to stan-
dard methods for HCV therapy (26).
3.3. Explanation of Response
To specify the types of response to peg-IFNa-2a/RBV
combination therapy, the presence of genomic HCV RNA
was evaluated at the end of the therapy and 6 months
thereafter. The hepatitis C viral load was measured in the
plasma samples. According to the results of the HCV-RNA
evaluation at the aforesaid time points, the cases were clas-
sified into three groups: sustained virological response
(SVR) that was named because of undetectable HCV RNA
at the end of 24 weeks; End-of-treatment (EOT) response
that was tested at 24 weeks after initiation of treatment for
HCV genotype 2 and 3 infections and at 48 weeks for geno-
type 1 of HCV; and Relapse response that happened when
HCV RNA reemerged in a patient who previously had ob-
tained an EOT response. All patients with detectable hep-
atitis virus RNA, at the end of the treatment and during
follow-up, were considered as non-responders (NR) (26, 27).
3.4. Indirect Immunofluorescence Assay (IIFA)
All samples were analyzed by IIF assay with HEp-2 slides
from Euroimmun (Lu¨ beck, Germany) at a screening di-
lution of 1/80 according to standard IIF protocol (28) with
EUROStar III PlusFlurescent microscope under 400 magni-
fications. Analyses were done separately by two expert ob-
servers of Firouzgar Hospital affiliated to Iran University
of Medical Sciences (IUMS). Images were captured using a
BASLER acA2500-14uc-Imager.
3.5. RNA Extraction and Genotyping
To determine HCV genotypes, viral RNA was extracted
from 140 µL of sera using the QIAamp Viral RNA Extrac-
tion kit (Qiagen GmbH, Hilden, Germany) based on the
manufacturer’s protocol. HCV-RNA in sera was detected
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by the reverse transcription-nested polymerase chain reac-
tion (RT-nested PCR) assay (29). The HCV genotypes were
analyzed in HCV-positive samples using restriction frag-
ment length polymorphism (RFLP) assay of the 5′-NCR of
the HCV genome as described previously (30).
3.6. Statistical Analysis
Statistical analyses were performed using SPSS version
17 (SPSS, Chicago, IL). Descriptive indices, Fisher’s exact test,
and Chi-square test were used. P values < 0.05 were consid-
ered statistically significant.
4. Results
120 patients chronically infected with HCV were en-
rolled in the current study and divided into three groups.
The groups were defined as SVR (n = 40), relapsers (n = 40),
and spontaneous clearance (n = 40). The mean age (±SD)
of the patients was 43± 13.2 (range of 17 - 71 years). Among
120 patients, 90 (75%) were male. Clinical data on biochemi-
cal parameters, virological aspects, and type of therapeutic
response (using One-way ANOVA and Chi-square test) are
presented in Table 1.
Anti-rod and ring antibodies (Anti-RR Abs) were read-
ily identified on Euroimmun HEp-2 slides. The abovemen-
tioned autoantibodies were detected in only one serum of
the 120 patients under the study (0.8%) that belonged to
one out of 40 patients with relapse response (2.5%) (Figure
1). No correlation was found between the type of response
to peg-IFNa-2a/RBV combination therapy and the presence
of anti-RR Abs (P = 0.365; Chi-square test). However, other
IIF-HEp-2 patterns were observed in variable proportions
in all groups of patients. The speckled cytoplasmic pattern
was the dominant pattern in the studied patients (Table 2).
Background information regarding autoimmune dis-
orders in the patients was also studied. Two patients (1.7%)
were positive, 77 patients (64.2%) were negative, and the
data of 41 patients (34.2%) were unknown. Among positive
patients, none of them had anti-RR reactivity; thus, any
association was not observed between having an autoim-
mune disease and the presence of anti-RR Abs (P = 1.000;
Fisher’s exact test).
The data of the present study show that only one pa-
tient had anti-RR reactivity, and 119 patients presented
other IIF-HEp-2 patterns or were negative for the IIF-HEp-2
test.
4. Discussion
This study showed that HCV infection is associated
with the type of immune reactions, part of which is re-
flected by the presence of organ and non-organ specific au-
toAbs. Probable mechanisms for the production of auto
Abs may include molecular mimicry, an interaction be-
tween the HCV and B cells which boosts their reproduction,
or direct infection of the immune cells by HCV (31).
In one study by Keppeke et al. cell cultures treated with
ribavirin demonstrated that this drug has the potential to
induce the formation of the RR pattern; in other words,
only HCV positive patients, treated with peg-IFNa-2a/RBV
combination therapy, had anti-RR Abs, whereas none of
the untreated ones showed this pattern (28). In this study,
none of the samples from the spontaneous clearance pa-
tients without any treatment method were positive for an
RR pattern (28).
In another study by Felisberto et al. the presence of
anti-RR Abs was observed just after the beginning of treat-
ment. In 6% of patients, its appearance started within the
first month; however, after 6 months, > 47% of the sam-
ples presented with the RR pattern. Another finding of the
study was that, among anti-RR-positive patients, 77% did
not respond to the treatment. On the other hand, among
anti-RR-negative patients, the rate was 64%. Thus, this pat-
tern is not related to the success of peg-IFNa-2a/RBV combi-
nation therapy (32).
The presence of autoantibodies to cytoplasmic RR par-
ticles in the serum of patients with chronic HCV Infec-
tion has been reported in various populations around the
world. For example, it was detected in 14.1% of 342 HCV
infected patients and 38% of 108 patients receiving Peg-
IFN/RBV, but it was present in none of 166 untreated pa-
tients (28). In the study by Covini et al. analyses revealed
the presence of antibodies to rod-like cytoplasmic struc-
tures in 15 out of 75 (20%) patients with chronic hepati-
tis C. Anti-RR antibodies were found in sera collected only
during Peg-IFN/RBV treatment; but they were never de-
tected before antiviral therapy or even in control groups.
However, the antibodies were detected more often in non-
responder/relapsers than responder patients (33% versus
11%) (24). In another study, about 20-35% of HCV pa-
tients treated with Peg-IFN/RBV combination therapy were
known to induce the production of anti-RR antibodies af-
ter several weeks or months (24, 33).
In the current study, the RR pattern was only observed
in one case out of 120 HCV patients (0.8%) that was classi-
fied in the relapse group. The RR pattern was not shown in
any of subjects who have been categorized in the SVR and
spontaneous clearance groups. No correlation was found
between the success of peg-IFNa-2a/RBV combination ther-
apy and the presence of anti-RR Abs. The low prevalence
of anti-RR in the Iranian HCV patients is intriguing and
maybe related to genetics and environmental factors; how-
ever, there is no follow-up information in this regard here.
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Table 1. Clinical Information of the Patients and Various Types of Therapeutic Responses to Pegylated- Interferon Alfa-2a and Ribavirin Combination Therapya
Patients SVRb Relapse SCc Total P Value
No. of patients 40 (33 ) 40 (33 ) 40 (33 ) 120 (100)
Gender Male/female 34/6 32/8 24/16 90/30 0.024 Chi-square test
Age, y 37.6± 10.7 (17 - 67) 43.8± 13.04 (19 - 69) 59.2± 6.4 (53 - 71) 43± 13.1 (17 - 71) < 0.001One-way ANOVA
Laboratory Parameters
Pre ALTd , IU/L 78.2± 59.2 (18 - 275) 72.8± 41.1 (17 - 197) 15.2± 9.1 (1 - 41) 61± 51.4 (1 - 275) < 0.001a One-way ANOVA
Post ALT, IU/L 26.1± 13 (9 - 60) 34.9± 20.4 (8 - 94) 15.4± 8.5 (2 - 40) 30.4± 17.5 (8 - 94) < 0.001 One-way ANOVA
Pre AST, IU/L 53.6± 47.2 (19 - 309) 60.4± 35.8 (15 - 172) 16.4± 6.2 (3 - 29) 47.2± 40.5 (3 - 309) < 0.001 One-way ANOVA
Post ASTe , IU/L 27.6± 12.1 (14 - 67) 35.3± 19.9 (8 - 106) 16.5± 6.2 (4 - 29) 31.4± 16.7 (8 - 106) < 0.001 One-way ANOVA
Pre ALPf , IU/L 197.3± 67.5 (76 - 364) 231.1± 77.8 (87 - 415) 230.1± 54.7 (153 - 349) 217.9± 70.1 (76 - 415) 0.061 One-way ANOVA
Post ALP, IU/L 189± 56.2 (90 - 329) 207.7± 81.5 (62-414) 230.3± 54.6 (156 - 350) 198.3± 70 (62 - 414) 0.056 One-way ANOVA
Pre GGTg , IU/L 40.5±23.2 (14 - 122) 76.1± 61.7 (12-247) 23.6± 13 (11-67) 49.2± 45.4 (11 - 247) < 0.001 One-way ANOVA
VLDLh , mmol/L 24.7± 23.4 (7 - 130) 22± 10.1 (4 - 40) 20± 13.2 (6-89) 23.3± 17.6 (4 - 130) 0.578 One-way ANOVA
Clinical Information
No. of Cirrhotic patients 0 3 (7.5) 0 3 (2.5) 0.046 Chi-square test
HCV Genotypes/Subtypes
1a 19 (47.5) 17 (42.5) 0 36 (30)
< 0.001 Chi-square test
1a/1b 0 0 4 (10) 4 (3.3)
1b 2 (5) 5 (12.5) 0 7 (5.8)
2b 1 (2.5) 0 0 1 (0.8)
3a 18 (45) 13 (32.5) 0 31 (25.8)
aValues are expressed as No. (%).
bSustained virological response.
cSpontaneous clearance.
dPretreatment Alanine aminotransferase (ALT).
ePost treatment Aspartate aminotransferase (AST).
f Very-low-density lipoprotein (VLDL).
gAlkaline phosphatase (ALP).
hGamma-glutamyl transpeptidase (GGT).
Therefore, it seems that more studies need to be done in
this area.
In conclusion, the present study independently con-
firmed the association of the IIF-HEp-2 RR pattern with
HCV and found no association between the presence of
anti-RR Abs and different groups in responding to the peg-
IFNa-2a/RBV combination therapy. In addition, the cur-
rent study was able to limit the trigger of anti-RR reactiv-
ity to the peg-IFNa-2a/RBV combination therapy. On the
other hand, no association was detected between demo-
graphic parameters, response to treatment, HCV genotype,
and having an autoimmune disease. Despite the clear as-
sociation of anti-RR reactivity and peg-IFNa-2a/RBV combi-
nation therapy, it is striking that the majority (98.8%) of
Iranian patients under the mentioned therapy showed no
anti-RR reactivity.
According to this study, the rate of the presence of anti-
RR Abs is extremely rare in Iranian patients treated with
Peg-IFN/RBV. On the other hand, the genetic background
could be an important factor for this discrepancy, which
needs more comprehensive studies and research.
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Figure 1. Indirect Immunofluorescence - Hep - 2 Rods and Rings Pattern
IIF with a representative anti-Rods and Rings positive HCV patient sample diluted 1/80. A and B, slides from Euroimmun; A, cells with rods and rings conformations at× 40
magnification; B, classical RR at× 10 magnification. Bar, 5µm.
Table 2. Distribution of Patients with Hepatitis C Virus and Other Hepatic and Non-Hepatic Diseases According to the Presence of Anti-Rod and Ring Antibodies and Other
Indirect Immunofluorescencee-HEp-2 Patternsa
Types of Responses
IIF-HEp-2 Patternsb SVRc (n = 40) Relapse (N = 40) SCd (N = 40) P Value
Nucleoli 4 (10) 11 (27.5) 6 (15) 0.105 Chi-square test
FSe 4 (10) 2 (5) 2 (5) 0.585 Chi-square test
Midbody 0 3 (7.5) 2 (5) 0.232 Chi-square test
SCPf 17 (42.5) 15 (37.5) 11 (27.5) 0.362 Chi-square test
Mitotic spindle 0 1 (2.5) 3 (7.5) 0.164 Chi-square test
Rods and rings 0 1 (2.5) 0 0.365 Chi-square test
Overall IIF-Hep-2 Reactivity 25 (62.5) 33 (82.5) 24 (60)
aValues are expressed as No. (%).
bIIF-HEp-2 patterns were based on observation using Euroimmun slides.
cSustained virological response.
dSpontaneous Clearance.
eFine Speckled.
f Speckled Cytoplasmic Pattern.
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